A peripheral nerve stimulator is a device that delivers mild electrical pulses to a specific nerve outside the brain and spinal cord, interrupting pain signals before they reach the central nervous system. The concept dates back to the 1960s, when researchers first tested whether stimulating a peripheral nerve could reduce the perception of pain, and the field has expanded dramatically since then. Modern versions range from temporary, wire-thin leads placed through a needle to fully implantable systems with rechargeable pulse generators. The science, the hardware, and the list of conditions these devices can treat have all changed faster in the last decade than in the previous four combined.
How Peripheral Nerve Stimulation Works
The dominant explanation for why sending electricity into a nerve reduces pain comes from the gate control theory, proposed by Ronald Melzack and Patrick Wall in the 1960s. The core idea is that non-painful sensory signals can effectively “close a gate” in the spinal cord, blocking pain signals from traveling up to the brain. A peripheral nerve stimulator activates large-diameter sensory fibers in or near the target nerve, and those signals compete with and suppress the smaller pain-carrying fibers. Most of what clinicians understand about why peripheral nerve stimulation works still rests on this framework, though the full picture remains incomplete.1PubMed Central. Mechanism of Action of Peripheral Nerve Stimulation for Chronic Pain: A Narrative Review
What makes this more than just a fancy TENS unit is the precision of where the electrical signal is delivered. Rather than sending current through the skin and hoping it reaches the right nerve, a peripheral nerve stimulator places an electrode right next to the nerve itself, sometimes within millimeters. That proximity lets the device use lower energy levels while achieving a stronger, more targeted effect. The sensation patients feel during stimulation varies: some describe tingling or gentle buzzing in the area the nerve supplies, while others report feeling almost nothing at all depending on the settings.
A Brief History
The roots of electrical nerve stimulation go surprisingly far back. The first documented use of electrostimulation is attributed to Scribonius Largus in ancient Rome around 47 CE, who reportedly used electric eels to treat pain. The modern era began in the 1800s, when Michael Faraday’s work on electromagnetic induction laid the groundwork, and a German-English physician named Julius Althaus reported directly stimulating a peripheral nerve to ease surgical pain. In the 1960s, Melzack and Wall’s gate control theory gave clinicians a rationale for the approach, and Patrick Wall and William Sweet were the first to verify it by stimulating their own nerves in a lab.2Pain Medicine. History of Peripheral Nerve Stimulation—Update for the 21st Century
From the 1980s onward, commercially available multi-contact electrodes and implantable pulse generators turned peripheral nerve stimulation from a laboratory curiosity into a clinical tool. The biggest shift in recent years has been the rise of percutaneous techniques, where thin leads are threaded through a needle under imaging guidance rather than requiring open surgery to expose the nerve.3PubMed. History of peripheral nerve stimulation This made the procedure far less invasive and opened it up to a wider range of patients and clinical settings.
How the Devices Are Placed
Most peripheral nerve stimulator leads today are placed using ultrasound guidance. The clinician uses a real-time ultrasound image to visualize the target nerve, then advances a thin electrode through a needle until it sits close to the nerve. This approach avoids surgical exploration entirely. Early cadaver studies mapped out where electrodes could be safely positioned around lower-extremity nerves, identifying spots along the tibial nerve above the ankle, the peroneal nerve near the fibular head, and the sciatic nerve at the upper popliteal fossa, among others, all without visible neural injury.4Regional Anesthesia and Pain Medicine. Feasibility of Ultrasound-Guided Percutaneous Placement of Peripheral Nerve Stimulation Electrodes in a Cadaver Model: Part One, Lower Extremity
The same ultrasound-guided percutaneous technique has been applied to upper-extremity nerves as well. Clinicians have described placing permanent stimulator leads along the femoral nerve using ultrasound alone, achieving precise positioning without any surgical cut-down.5PubMed. Ultrasound-guided placement of a permanent percutaneous femoral nerve stimulator leads for the treatment of intractable femoral neuropathy The widespread adoption of point-of-care ultrasound across pain medicine and anesthesiology has been a major driver of PNS growth, because it lets practitioners who are already comfortable with ultrasound-guided nerve blocks adapt their skills to electrode placement.
Temporary Versus Permanent Systems
One distinction that can confuse patients and even some clinicians is the difference between a temporary system, a permanent implant, and the newer 60-day treatment approach. A traditional trial involves placing a temporary lead for a few days to a week to see if the patient responds, then deciding whether to implant a permanent device with a surgically placed pulse generator. The 60-day approach, developed more recently, uses a percutaneous lead that stays in place for up to 60 days and is then removed entirely, with the therapeutic effects often outlasting the treatment period itself.6PubMed Central. Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy
The idea behind the 60-day system is that sustained stimulation over weeks can produce lasting changes in how the nervous system processes pain, so a permanent implant may not be necessary. For many patients, this is appealing because it avoids the long-term commitment and maintenance of an implanted device. Not everyone gets lasting relief from the temporary approach, though, and some will go on to receive a permanent system afterward.
Conditions Treated With Peripheral Nerve Stimulation
The range of pain conditions that peripheral nerve stimulators address has grown considerably. The technology is no longer limited to a single niche; it now spans amputation pain, headache disorders, joint pain, back pain, and post-stroke complications, among others.
Post-Amputation and Phantom Limb Pain
Phantom limb pain, where an amputee feels persistent pain in a limb that is no longer there, is notoriously difficult to treat with medications alone. In a randomized, placebo-controlled trial, about 58% of patients receiving peripheral nerve stimulation achieved at least a 50% reduction in their post-amputation pain during the first four weeks, compared with only 14% of those receiving a sham treatment. After eight weeks, roughly two-thirds of the stimulation group still reported that level of relief, along with meaningful reductions in how much the pain interfered with daily life.7Regional Anesthesia & Pain Medicine. Percutaneous peripheral nerve stimulation for the treatment of chronic neuropathic postamputation pain: a multicenter, randomized, placebo-controlled trial Smaller case series have echoed those findings, with amputee patients reporting substantial improvement in both pain and physical function after temporary PNS placement.8PubMed Central. Peripheral Nerve Stimulation for the Treatment of Phantom Limb Pain: A Case Series
Hemiplegic Shoulder Pain After Stroke
Shoulder pain after a stroke is common and can severely limit rehabilitation. A randomized controlled trial comparing peripheral nerve stimulation to usual care found that patients in the stimulation group went from an average pain severity of about 7.5 out of 10 down to roughly 3.2 at ten weeks, while the usual-care group barely budged, going from 7.6 to 6.1. That gap held at 16 weeks.9PubMed Central. Peripheral Nerve Stimulation Compared to Usual Care for Pain Relief of Hemiplegic Shoulder Pain: A Randomized Controlled Trial In a longer follow-up case series using a fully implantable system, all five participants maintained at least a 50% pain reduction at one year, and four of the five kept that level of relief at two years, with improved shoulder range of motion and no serious device-related complications.10PubMed Central. Fully Implantable Peripheral Nerve Stimulation for Hemiplegic Shoulder Pain: A Multi-Site Case Series with Two-Year Follow-up
Chronic Migraine and Occipital Neuralgia
Stimulating the occipital nerves at the back of the skull has become one of the more studied applications for refractory chronic migraine. In a randomized, double-blinded trial, patients who received active occipital nerve stimulation saw their monthly headache days drop by about six days on average (from a baseline of around 22), compared with a three-day drop in the sham group.11PubMed. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study A long-term prospective study followed patients for up to seven years and found benefits were maintained over that span.12PubMed. Occipital Nerve Stimulation for Refractory Chronic Migraine: Results of a Long-Term Prospective Study
A single-center cohort of 53 chronic migraine patients, followed for a median of about three and a half years, saw moderate-to-severe headache days drop by roughly eight to nine days per month. The response rate, defined as at least a 30% reduction in those severe headache days, was about 45% of the full group, and patients with multiple overlapping headache types did even better, with a response rate close to 67%.13PubMed Central. Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients These patients had already failed an average of nine preventive medications before getting the implant, so the population is heavily treatment-resistant.
Knee and Musculoskeletal Pain
Chronic knee pain, whether from osteoarthritis, prior surgery, or injury, has emerged as a target. In one study, median pain scores at rest dropped from 8 out of 10 before the procedure to 3 afterward, and held at 2 at both three and six months.14Scientific Reports. Peripheral nerve stimulation for the treatment of chronic knee pain A separate case series found a mean pain reduction of about 52% at six months, with three-quarters of patients achieving at least a 50% drop and no adverse events reported.15PubMed Central. Peripheral Nerve Stimulation in Chronic Knee Pain: A Case Series Even complex cases, like a patient with chronic pain after a total knee replacement and a non-operable patella fracture, have responded: one such patient achieved enough relief to wean off all opioid medications within three months.16PubMed Central. Peripheral Nerve Stimulation After Total Knee Arthroplasty and Non-Operable Patella Fracture
Chronic Low Back Pain
Back pain is the most common chronic pain complaint worldwide, and peripheral nerve stimulation targeting the medial branch nerves in the lumbar spine has shown early promise. In a study of patients who had previously undergone radiofrequency ablation, two-thirds reported at least a 50% reduction in pain intensity after two months of stimulation, and the vast majority saw meaningful improvements in disability and pain interference with daily activities.17PubMed Central. Percutaneous Peripheral Nerve Stimulation of the Medial Branch Nerves for the Treatment of Chronic Axial Back Pain in Patients After Radiofrequency Ablation A multicenter clinical trial using a 60-day percutaneous approach described it as a safe and effective first-line neuromodulation treatment for chronic low back pain that had not responded to other non-surgical therapies.18Interventional Pain Medicine. Durable patient-reported outcomes following 60-day percutaneous peripheral nerve stimulation (PNS) of the medial branch nerves
Safety and Complications
Peripheral nerve stimulation is generally considered low-risk, especially when compared to spinal cord stimulation or repeated surgeries, but it is not complication-free. The most commonly reported problems include infection at the lead site, migration of the electrode away from its intended position, and lead fracture.19PubMed Central. Difficult removal of exposed peripheral nerve stimulator leads: a report of 2 cases Hardware-related issues, particularly lead migration, remain the most frequent concern across device types.20ScienceDirect. A Modern Atlas for Implantable Devices of the Spine, Brain, and Nerve Temporary systems sidestep some of these problems because the leads are designed to be removed after a set period, but they carry their own risk of site irritation or difficulty during removal if tissue grows around the lead.
Serious neurological injury is rare. The large occipital nerve stimulation cohort mentioned earlier reported no episodes of lead migration and only one minor infection across 53 patients over years of follow-up. Still, any time a foreign body sits near a nerve for weeks or months, there is at least a theoretical risk of nerve irritation or damage, and patients should be aware of that going in.
The Opioid Question
One of the most common selling points for peripheral nerve stimulation is that it can help patients reduce or eliminate opioid medications. The evidence here is mixed and worth understanding carefully. A retrospective case series found that among patients with baseline opioid use, median daily opioid consumption dropped substantially at six months after implantation, alongside a roughly 73% self-reported functional improvement.21PubMed. Peripheral Nerve Stimulation and Clinical Outcomes: A Retrospective Case Series A systematic review described a small study where more than 83% of low back pain patients experienced at least a 50% reduction in analgesic medication use, lasting up to seven months.22PubMed Central. Peripheral Nerve Stimulation in Pain Management: A Systematic Review
However, a larger two-year multicenter analysis tells a more cautious story. When researchers measured daily opioid consumption in milligram equivalents, there was no statistically significant change at six months or twelve months compared to baseline, regardless of whether the patient had a temporary or permanent system.23PubMed Central. Pain intensity and opioid consumption after temporary and permanent peripheral nerve stimulation: a 2-year multicenter analysis The discrepancy likely reflects the difference between carefully selected case series (which tend to show dramatic results) and larger real-world populations (where outcomes are more variable). The honest takeaway is that some patients do reduce their opioids meaningfully, but it is not guaranteed, and clinicians should not promise opioid elimination as a standard outcome.
Costs and Healthcare Utilization
Pain is expensive, not just in medication costs but in emergency visits, imaging, specialist appointments, and lost productivity. A real-world analysis of 122 patients with a permanently implanted micro-pulse-generator system found that total median medical costs dropped by about 57% after implantation, and the proportion of patients using opioids fell by roughly 31%.24PubMed Central. Real-world healthcare utilization and costs of peripheral nerve stimulation with a micro-IPG system When comparing the 60-day temporary approach to the traditional trial-then-permanent-implant pathway, the 60-day route came out considerably cheaper per successful outcome, in large part because it avoids the cost of a permanent implant for patients who end up not needing one.25PubMed Central. Cost Savings in Chronic Pain Patients Initiating Peripheral Nerve Stimulation (PNS) with a 60-Day PNS Treatment
Who Is a Good Candidate
Patient selection matters more here than with most treatments, because peripheral nerve stimulation works on a specific mechanism: it modulates a particular nerve’s signaling. If the pain is not primarily driven by the nerve being targeted, the device will not help. Clinical guidelines recommend adequate screening before implantation, and most practitioners use a diagnostic nerve block or a stimulation trial as part of the decision process.26PubMed Central. Evidence-Based Clinical Guidelines from the American Society of Pain and Neuroscience for the Use of Implantable Peripheral Nerve Stimulation in the Treatment of Chronic Pain
Interestingly, though, expert consensus guidelines have noted that diagnostic nerve blocks do not actually predict who will respond to stimulation. A review evaluating nerve blocks before PNS implantation found no outcome difference at three and six months between patients who had a positive block and those who did not. The likely explanation is that a local anesthetic and an electrical stimulator work through completely different mechanisms, so a block that dulls the nerve temporarily is not a reliable preview of what sustained stimulation will accomplish.27PubMed Central. Expert Opinion Consensus Guidelines for the Use of Peripheral Nerve Stimulation in the Treatment of Chronic Pain and Neurological Diseases This is one of the more counterintuitive findings in the field, and it means clinicians are still refining how best to identify the right patients.
Peripheral Nerve Stimulation in Children
Most of the research on PNS has been in adults, but interest in treating adolescents is growing. Neuropathic pain in children is often undertreated, partly because many adult pain interventions are not well-studied in younger populations. Case reports have described the 60-day percutaneous approach being used successfully in adolescent patients, reducing pain and disability without medications and their potential side effects.28Pediatrics. Peripheral Nerve Stimulation for the Management of Pediatric Neuropathic Pain Even adolescent cancer patients with severe shoulder pain have been treated with PNS, with two patients reporting roughly 60% pain relief that persisted up to 90 days after the leads were removed.29PubMed Central. Suprascapular nerve peripheral nerve stimulation for pediatric cancer pain: a case series
There are practical limits, however. PNS is generally not recommended for children younger than ten, because younger kids may not be able to describe their pain accurately or handle the external components of the device. Cognitively delayed children face similar challenges. For adolescents who can cooperate with the process, though, the risk profile appears similar to adults, and the ability to avoid systemic medications is a particularly attractive feature in a developing body.
Emerging Technology
The devices themselves are evolving quickly. One of the more intriguing developments is bioresorbable stimulators: devices that do their job and then dissolve harmlessly inside the body, eliminating the need for a removal procedure entirely. Researchers have demonstrated a wireless, bioresorbable dual stimulator for peripheral nerve regeneration, with engineering advances that extended its stable operational lifetime in living tissue by roughly five times compared to earlier designs.30Nature Communications. Bioresorbable, wireless dual stimulator for peripheral nerve regeneration These are still in the experimental stage, but the trajectory suggests that future temporary PNS systems may not require any lead removal at all.
Closed-loop systems represent another frontier. Current stimulators deliver a pre-set pattern of electrical pulses regardless of what the nerve is doing at any given moment. A closed-loop system would sense the nerve’s real-time activity and adjust stimulation automatically, much like a thermostat adjusts a furnace. Proof-of-concept work in animal models has shown that mathematical models of pain-related nerve activity can be used to guide closed-loop peripheral nerve stimulation, steering nerve responses back toward normal patterns.31PubMed Central. Steering Toward Normative Wide-Dynamic-Range Neuron Activity in Nerve-Injured Rats With Closed-Loop Peripheral Nerve Stimulation Separately, engineers have developed soft, self-healing electrode materials paired with machine-learning algorithms that could enable neuroprosthetic systems to adapt over long periods of wear, correcting for the gradual material fatigue that currently limits implanted devices.32PubMed Central. Performance-Recoverable Closed-Loop Neuroprosthetic System None of this is available commercially yet, but the gap between lab and clinic in neuromodulation has been shrinking steadily.